1 results match your criteria: "and Metabolism (M.E.D.) and Clinical Pharmacology (R.Q.)[Affiliation]"
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
Drug Metab Dispos
June 2024
Pharmacokinetics, Dynamics, and Metabolism (M.E.D.) and Clinical Pharmacology (R.Q.), Pfizer Inc., Cambridge, Massachusetts and Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut (Al.D., M.N., An.D., A.B., S.W.W., G.S.W., R.S.)
Brepocitinib is an oral once-daily Janus kinase 1 and Tyrosine kinase 2 selective inhibitor currently in development for the treatment of several autoimmune disorders. Mass balance and metabolic profiles were determined using accelerator mass spectrometry in six healthy male participants following a single oral 60 mg dose of C-brepocitinib (∼300 nCi). The average mass balance recovery was 96.
View Article and Find Full Text PDF